Chemistry:Afabicin
From HandWiki
Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections. It is a prodrug which is converted in vivo into the active form afabicin desphosphono (Debio 1452) which acts as an inhibitor of the staphylococcal enoyl-acyl carrier protein reductase (FabI) enzyme. It has shown similar efficacy in clinical trials to established drugs such as vancomycin, but has not yet been approved for clinical use.[1][2][3][4][5][6]
See also
- Mupirocin
- Nilofabicin
References
- ↑ "Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery". Antimicrobial Agents and Chemotherapy 63 (3). March 2019. doi:10.1128/AAC.01669-18. PMID 30559136.
- ↑ "Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials". Expert Opinion on Investigational Drugs 29 (5): 495–506. May 2020. doi:10.1080/13543784.2020.1750595. PMID 32242469.
- ↑ "Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid". Antimicrobial Agents and Chemotherapy 64 (10). September 2020. doi:10.1128/AAC.00250-20. PMID 32747361.
- ↑ "Antibiotics with novel mode of action as new weapons to fight antimicrobial resistance". European Journal of Medicinal Chemistry 256. August 2023. doi:10.1016/j.ejmech.2023.115413. PMID 37150058.
- ↑ "A Review of Fatty Acid Biosynthesis Enzyme Inhibitors as Promising Antimicrobial Drugs". Pharmaceuticals 16 (3): 425. March 2023. doi:10.3390/ph16030425. PMID 36986522.
- ↑ "Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin". The Journal of Antimicrobial Chemotherapy 78 (8): 1900–1908. August 2023. doi:10.1093/jac/dkad181. PMID 37294305.
 |  |
